{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 406050182
| IUPAC_name = 4-(5,6,7,8-Tetrahydroimidazo[1,5-''a'']pyridin-5-yl)benzonitrile
| image = Fadrozole structure.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 102676-47-1
| CAS_number2_Ref = {{cascite|correct|CAS}}
| CAS_number2 = 102676-31-3
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 59693
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 53850
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = CLPFFLWZZBQMAO-UHFFFAOYSA-N  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = H3988M64PU
| UNII2_Ref = {{fdacite|correct|FDA}}
| UNII2 = H0Q44H4ECQ
| index2_label= hydrochloride
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02451
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 9298

<!--Chemical data-->
| chemical_formula =  
| C=14 | H=13 | N=3 
| molecular_weight = 223.27 g/mol
| smiles = C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N
}}

'''Fadrozole''' ([[International Nonproprietary Name|INN]], marketed as '''Afema''' by [[Novartis]]) is a selective<ref name="pmid1825337">{{cite journal |vauthors=Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A |title=Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease |journal=J. Med. Chem. |volume=34 |issue=2 |pages=725–36 |date=February 1991 |pmid=1825337 |doi= 10.1021/jm00106a038|url=}}</ref> [[aromatase inhibitor]]<ref name="pmid1530798">{{cite journal |vauthors=Raats JI, Falkson G, Falkson HC |title=A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer |journal=J. Clin. Oncol. |volume=10 |issue=1 |pages=111–6 |date=January 1992 |pmid=1530798 |doi= 10.1200/jco.1992.10.1.111|url=http://www.jco.org/cgi/pmidlookup?view=long&pmid=1530798|doi-broken-date=2017-02-11 }}</ref> that has been introduced in [[Japan]] for the treatment of  [[breast cancer]].

==References==
{{Reflist}}

{{Antiestrogens}}
{{Androgenics}}
{{Estrogenics}}

[[Category:11β-Hydroxylase inhibitors]]
[[Category:27-Hydroxylase inhibitors]]
[[Category:Aldosterone synthase inhibitors]]
[[Category:Aromatase inhibitors]]
[[Category:Hormonal antineoplastic drugs]]
[[Category:Imidazopyridines]]
[[Category:Nitriles]]


{{antineoplastic-drug-stub}}